Nebenwirkungen · Olanzapine Teva
Olanzapine Teva 5 mg orodispersible tablets Olanzapine Teva 10 mg orodispersible tablets Olanzapine Teva 15 mg orodispersible tablets Olanzapine Teva 20 mg orodispersible tablets · Abschnitt 4.8 · PDF-Seite 26
HOS-209098 · Präparat HOS-154237
Adults The most frequently (seen in ≥1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-12T13:49:00Z · SHA-256 4c6933e864732db54f617a6615c3605a1299041a617de136aab779c18c8dbbe1 · Passage c818a35a3903744fa97b5b5c86ccc25d525d9b91dd5aab4f88fca71496daa992 · Zeichen 31–717 im Abschnitt